Tonix Pharmaceuticals Holding (TNXP) Consolidated Net Income (2011 - 2026)
Tonix Pharmaceuticals Holding (TNXP) posted quarterly Consolidated Net Income of -$40.3 million for Q1 2026, down 155.66% year-over-year from $72.5 million in Q1 2025, and up 14.07% quarter-over-quarter from -$46.9 million in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) Consolidated Net Income (2011 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's Consolidated Net Income history runs 16 years deep, the most recent figure standing at -$40.3 million for Q1 2026.
- In Q1 2026, Consolidated Net Income fell 155.66% year-over-year to -$40.3 million; the TTM figure through Mar 2026 stood at -$147.5 million (down 9.97% YoY), while the FY2025 annual figure was -$127.7 million, up 36.02% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$40.3 million, up from -$46.9 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$15.8 million in Q1 2025, with the low at -$78.9 million in Q2 2024.
- The 5-year median for Consolidated Net Income is -$29.1 million (2022), against an average of -$31.4 million.
- The sharpest annual moves came in 2024 and 2025: Consolidated Net Income sank 170.68% in 2024, then surged 64.08% in 2025.
- Tonix Pharmaceuticals Holding's Consolidated Net Income stood at -$31.8 million in 2022, then rose by 17.26% to -$26.3 million in 2023, then advanced by 14.38% to -$22.5 million in 2024, then slumped by 108.18% to -$46.9 million in 2025, then rose by 14.07% to -$40.3 million in 2026.
- Business Quant data shows TNXP's Consolidated Net Income at -$40.3 million in Q1 2026, -$46.9 million in Q4 2025, and -$31.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Tonix Pharmaceuticals Holding | 213.43 Mn | 213.43 Mn | 12.84 Mn | -43.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.93 Mn |
| Mar 31, 2026 | -40.34 Mn |
| Dec 31, 2025 | -46.94 Mn |
| Sep 30, 2025 | -31.87 Mn |
| Jun 30, 2025 | -28.34 Mn |
| Mar 31, 2025 | -15.78 Mn |
| Dec 31, 2024 | -22.55 Mn |
| Sep 30, 2024 | -16.90 Mn |
| Jun 30, 2024 | -78.89 Mn |
| Mar 31, 2024 | -23.14 Mn |
| Dec 31, 2023 | -26.34 Mn |
| Sep 30, 2023 | -29.23 Mn |
| Jun 30, 2023 | -29.14 Mn |
| Mar 31, 2023 | -33.14 Mn |
| Dec 31, 2022 | -31.83 Mn |
| Sep 30, 2022 | -29.14 Mn |
| Jun 30, 2022 | -24.15 Mn |
| Mar 31, 2022 | -26.57 Mn |
| Dec 31, 2021 | -29.71 Mn |
| Sep 30, 2021 | -18.67 Mn |